Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

December 2, 2024

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Pemetrexed, Carboplatin, Pembrolizumab

"* Pemetrexed 500mg/m2~* Carboplatin AUC 5.0~* Pembrolizumab 200mg"

DRUG

Paclitaxel, Carboplatin, Pembrolizumab

"* Paclitaxel 200mg/m2~* Caboplatin AUC 6.0~* Pembrolizumab 200mg"

Trial Locations (1)

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Samsung Medical Center

OTHER